Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 17, 2014– AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company’s hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company’s inhibitor of vascular endothelial growth factor (VEGF) 1, 2, and 3 receptors, will be presented at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, September 26 – September 30, 2014.

Download PDF Ficlatuzumab Phase 2 NSCLC Data and Tivozanib Phase 2 CRC and RCC Data to Be Presented at ESMO 2014 CongressAV-380 Preclinical Data to Be Presented at 2nd Cancer Cachexia Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 11, 2014– AVEO Oncology (NASDAQ:AVEO) today reported its second quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan. “Our

Download PDF CAMBRIDGE, Mass. & CHICAGO–(BUSINESS WIRE)–May 31, 2014– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 28, 2014– AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2014 at 8:30AM (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay of the webcast

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 7, 2014– AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan. “We made solid progress executing on a key component of our recently announced corporate strategy, which is to advance our clinical-stage assets through collaborations while retaining substantial

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 5, 2014– AVEO Oncology (NASDAQ: AVEO) today announced that the company will release its financial results for the first quarter ended March 31, 2014 after market close on Wednesday, May 7, 2014. Management plans to host financial results conference calls on a semi-annual basis, with the Company’s next conference call in August 2014. At that time, the

Download PDF Biodesix to Fund Proof of Concept Study CAMBRIDGE, Mass. & BOULDER, Colo.–(BUSINESS WIRE)–Apr. 10, 2014– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat®, a

Download PDF Agreement with Biogen Idec allows AVEO to seek partner to accelerate clinical development CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 20, 2014– AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec. “We are pleased to regain rights for AV-203 as we believe in the potential of this innovative therapy and